Last reviewed · How we verify
NCT07403669: CHAPERONE-CKM
Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment
NA trial testing CHAPERONE AI in Acute MI in 300 participants. Currently enrolling.
22 October 2026
Quick facts
| Lead sponsor | Aventyn, Inc. |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 300 |
| Start date | 22 October 2025 |
| Primary completion | 22 October 2026 |
| Estimated completion | 22 April 2027 |
| Sites | 5 locations across Sweden, United States |
Drugs / interventions tested
- CHAPERONE AI
- CKMiq AI
- Quality of Life
Conditions studied
- Acute MI — all drugs for Acute MI →
- Heart Failure — all drugs for Heart Failure →
- Diabetes Mellitus — all drugs for Diabetes Mellitus →
- Kidney Disease — all drugs for Kidney Disease →
Sponsor
Aventyn, Inc. — full company profile →
Who can join
18 and older, any sex, with Acute MI or Heart Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of CHAPERONE solution is to evaluate the efficacy of engaging, assessing, and enabling long term treatment strategy with Health Artificial Intelligence (AI) Chatbot, Copilot, Large Language Model (LLM) and vital sign monitoring device in reducing CKM disease burden using an algorithm obtained from biomarkers and diagnostics utilizing remote sensor driven technology tools, care coordination and patient empowerment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07403669
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute MI
Currently open trials in the same condition.
- NCT05515653 — Impact of the Genetic Background as a Risk Factor for Atherosclerotic Cardiovascular Disease in the Brazilian Population · active not recruiting
- NCT04905160 — Care Coordination to Assess Improvement in Outcomes in Hospital Readmissions · NA · recruiting
Other Aventyn, Inc. trials
Trials by the same sponsor.
- NCT04905160 — Care Coordination to Assess Improvement in Outcomes in Hospital Readmissions · NA · recruiting
- NCT04678193 — COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology Efficacy · recruiting
- NCT06330714 — Remote Monitoring of Chronic Illness Patients With a IHAP Home Wireless Hub and Vitals Measurements · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07403669 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aventyn, Inc.
- Last refreshed: 12 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07403669.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing